PT-141 (Bremelanotide)

Key Benefits#

• Enhances sexual desire and libido in both men and women
• Improves arousal through central nervous system activation
• Effective for psychological erectile dysfunction
• Works for female sexual arousal disorder
• May improve sexual satisfaction and intensity
• Fast-acting — effects within 45–60 minutes
• FDA-approved for HSDD in premenopausal women

Mechanism of Action#

PT-141 activates melanocortin receptors in the brain, particularly MC3R and MC4R, which are involved in sexual arousal regulation. Unlike PDE5 inhibitors (Viagra, Cialis) which act peripherally on blood vessels, PT-141 acts centrally on the nervous system to enhance sexual desire and arousal directly. This makes it effective for psychological and neurogenic sexual dysfunction, not just vascular causes.

Dosing Protocols#

Side Effects#

• Nausea (most common — 40% of users in clinical trials)
• Facial flushing and warmth
• Transient blood pressure changes (typically increase then normalize)
• Headache
• Spontaneous erections in men at higher doses
• Injection site bruising

Contraindications#

Uncontrolled hypertension or cardiovascular disease. Pregnancy or breastfeeding. Limit to 8 doses per month. Do not use with medications that slow heart rate.

Storage#

Refrigerate autoinjector or reconstituted solution at 2–8°C. Pre-filled autoinjector should be warmed to room temperature before use.

Featured In Stacks#

1. 1.
   Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer

   Mihulka O, Curran M, Narasimhan RM, Moore JF, Rojas KE · Journal of minimally invasive gynecology · 2025PubMed Verified

2. 2.
   Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies

   Fuhrman J, Yun J, Indorf A · Expert review of clinical pharmacology · 2025ReviewPubMed Verified

3. 3.
   Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases

   Bardhan M, Anand A, Javed A, Chilo MA, Khan N, Garg T et al. · Diseases (Basel, Switzerland) · 2025ReviewPubMed Verified

4. 4.
   FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach

   Serilmez M, Abuelrub A, Erol I, Durdaği S · Turkish journal of biology = Turk biyoloji dergisi · 2025PubMed Verified

5. 5.
   Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options

   Toledo RG, Winkelman WD, Reyes-Gonzalez D, Bergeron S, Fladger A, Hacker MR et al. · Journal of minimally invasive gynecology · 2026Meta-AnalysisPubMed Verified

6. 6.
   2024 SOGC, 2024 NCCN, 2022 ESO-ESMO, and 2018 ASCO: a comparison of female cancer survivorship guidelines for the management of sexual health concerns

   Bhinder JK, Kennedy SKF, Faouk Al Aadah C, Al-Khaifi M · Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025ReviewPubMed Verified

7. 7.
   A biodegradable suction patch for sustainable transbuccal peptide delivery

   Krupke H, Zoratto N, Rabut L, Gao D, Paunović N, Klein Cerrejon D et al. · Journal of controlled release : official journal of the Controlled Release Society · 2025PubMed Verified

8. 8.
   Bremelanotide

   2006ReviewPubMed Verified

9. 9.
   Novel Pharmacologic Treatments of Female Sexual Dysfunction

   How A, Jowdy C, Novatcheva E, Clayton AH · Clinical obstetrics and gynecology · 2025ReviewPubMed Verified

10. 10.
    Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder

    Borland JM, Kohut-Jackson AL, Peyla AC, Hall MA, Mermelstein PG, Meisel RL · Neuropharmacology · 2025PubMed Verified

11. 11.
    Gap in Sexual Dysfunction Management Between Male and Female Patients Seen in Primary Care: An Observational Study

    Stanley EE, Pfoh E, Lipold L, Martinez K · Journal of general internal medicine · 2025PubMed Verified

12. 12.
    Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression

    Suzuki S, Kitanaka C, Okada M · Anticancer research · 2024PubMed Verified

13. 13.
    Understanding the Interplay Between Premenstrual Dysphoric Disorder (PMDD) and Female Sexual Dysfunction (FSD)

    Gollapudi M, Thomas A, Yogarajah A, Ospina D, Daher JC, Rahman A et al. · Cureus · 2024ReviewPubMed Verified

14. 14.
    Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women

    Barakeh D, Mdaihly H, Karaoui LR · The Annals of pharmacotherapy · 2025ReviewPubMed Verified

15. 15.
    A Comprehensive Review of Novel FDA-Approved Psychiatric Medications (2018-2022)

    Giliberto S, Shishodia R, Nastruz M, Brar C, Bulathsinhala S, Terry J et al. · Cureus · 2024ReviewPubMed Verified

16. 16.
    First-time orgasm in a young man with lifelong anorgasmia after flibanserin use: a case report

    Saffati G, Naeem T, Kaaki B, Khera M · Sexual medicine · 2023Case ReportPubMed Verified

17. 17.
    Understanding Hypoactive Sexual Desire Disorder (HSDD) in Women: Etiology, Diagnosis, and Treatment

    Ronghe V, Pannase K, Gomase KP, Mahakalkar MG · Cureus · 2023ReviewPubMed Verified

18. 18.
    What Women Want? The State of the Art regarding the Treatment of Young Women with Hypoactive Sexual Desire Disorder

    de Oliveira L, Vignozzi L, Giraldi A, Varod S, Corona G, Reisman Y · Pharmacology · 2024ReviewPubMed Verified

19. 19.
    Targeting the central melanocortin system for the treatment of metabolic disorders

    Sweeney P, Gimenez LE, Hernandez CC, Cone RD · Nature reviews. Endocrinology · 2023ReviewPubMed Verified

20. 20.
    Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder

    Spielmans GI, Ellefson EM · Journal of sex research · 2024ReviewPubMed Verified

21. 21.
    Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study

    Safarinejad MR, Hosseini SY · The Journal of urology · 2023PubMed Verified

22. 22.
    Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin

    Yuan XC, Tao YX · Biomolecules · 2022ReviewPubMed Verified

23. 23.
    An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder

    Cipriani S, Alfaroli C, Maseroli E, Vignozzi L · Expert opinion on pharmacotherapy · 2023ReviewPubMed Verified

24. 24.
    Pharmacologic therapeutic options for sexual dysfunction

    Burton CS, Mishra K · Current opinion in obstetrics & gynecology · 2022ReviewPubMed Verified

25. 25.
    Finding Our Way From the Bench to the Bedside: The Ethos, Logos, and Pathos of Biomedical Research

    Kim NN · Sexual medicine reviews · 2022PubMed Verified

26. 26.
    Management of Hypertension with Female Sexual Dysfunction

    Zhong Q, Anderson Y · Medicina (Kaunas, Lithuania) · 2022ReviewPubMed Verified

27. 27.
    Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?

    Nappi RE, Tiranini L, Cucinella L, Martini E, Bosoni D, Righi A et al. · Expert opinion on pharmacotherapy · 2023PubMed Verified

28. 28.
    Medical Treatment of Female Sexual Dysfunction

    Nappi RE, Tiranini L, Martini E, Bosoni D, Righi A, Cucinella L · The Urologic clinics of North America · 2022ReviewPubMed Verified

29. 29.
    Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide

    Simon JA, Kingsberg SA, Portman D, Jordan R, Lucas J, Sadiq A et al. · Journal of women's health (2002) · 2022RCTPubMed Verified

30. 30.
    Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials

    Spana C, Jordan R, Fischkoff S · Diabetes, obesity & metabolism · 2022PubMed Verified

31. 31.
    Safety Profile of Bremelanotide Across the Clinical Development Program

    Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R et al. · Journal of women's health (2002) · 2022RCTPubMed Verified

32. 32.
    Female sexual dysfunctions: an overview on the available therapeutic interventions

    da Silva Lara LA, Rufino AC, Oliveira FF, Rossato S, Borges CS, Reis RM · Minerva obstetrics and gynecology · 2022ReviewPubMed Verified

33. 33.
    Pharmacotherapy for Sexual Dysfunction in Women

    Lee JH, Lee JE, Harsh V, Clayton AH · Current psychiatry reports · 2022ReviewPubMed Verified

34. 34.
    Bremelanotide for Treatment of Female Hypoactive Sexual Desire

    Edinoff AN, Sanders NM, Lewis KB, Apgar TL, Cornett EM, Kaye AM et al. · Neurology international · 2022ReviewPubMed Verified

35. 35.
    Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent

    Mintzes B, Tiefer L, Cosgrove L · Drug and therapeutics bulletin · 2021ReviewPubMed Verified

36. 36.
    Psychometric validation of the Female Sexual Distress Scale-Desire/Arousal/Orgasm

    Derogatis LR, Revicki DA, Rosen RC, Jordan R, Lucas J, Spana C · Journal of patient-reported outcomes · 2021PubMed Verified

37. 37.
    Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment

    Pettigrew JA, Novick AM · Journal of midwifery & women's health · 2021ReviewPubMed Verified

38. 38.
    Structural insights into ligand recognition and activation of the melanocortin-4 receptor

    Zhang H, Chen LN, Yang D, Mao C, Shen Q, Feng W et al. · Cell research · 2021PubMed Verified

39. 39.
    Bremelanotide

    2012ReviewPubMed Verified

40. 40.
    Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'"

    Kingsberg SA, Clayton AH, Portman D, Krop J, Jordan R, Lucas J et al. · Journal of sex research · 2021PubMed Verified

41. 41.
    Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women

    Spielmans GI · Journal of sex research · 2021Meta-AnalysisPubMed Verified

42. 42.
    Management of hypoactive sexual desire disorder in transgender women: a guide for clinicians

    Cocchetti C, Ristori J, Mazzoli F, Vignozzi L, Maggi M, Fisher AD · International journal of impotence research · 2020ReviewPubMed Verified

43. 43.
    The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results

    Koochaki P, Revicki D, Wilson H, Pokrzywinski R, Jordan R, Lucas J et al. · Journal of women's health (2002) · 2021RCTPubMed Verified

44. 44.
    The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women

    Pfaus JG, Sadiq A, Spana C, Clayton AH · CNS spectrums · 2022ReviewPubMed Verified

45. 45.
    LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs

    Mestria S, Odoardi S, Frison G, Strano Rossi S · Drug testing and analysis · 2021PubMed Verified

46. 46.
    Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder

    Revicki DA, Althof SE, Derogatis LR, Kingsberg SA, Wilson H, Sadiq A et al. · Journal of patient-reported outcomes · 2020PubMed Verified

47. 47.
    Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment

    Kingsberg SA, Simon JA · Journal of women's health (2002) · 2020PubMed Verified

48. 48.
    Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics

    Sauter M, Uhl P, Burhenne J, Haefeli WE · Journal of pharmaceutical and biomedical analysis · 2020PubMed Verified

49. 49.
    New Drugs 2020, part 2

    Hussar DA · Nursing · 2020PubMed Verified

50. 50.
    2019 FDA TIDES (Peptides and Oligonucleotides) Harvest

    Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG · Pharmaceuticals (Basel, Switzerland) · 2020ReviewPubMed Verified